SCHEMBL177682

SCHEMBL177682

O=C1C=CC(=O)c2c(O)ccnc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.54
TXNRD1 Q16881 3/20 0.54
AURKA O14965 2/20 0.54
AURKB Q96GD4 2/20 0.54
TXNRD3 Q86VQ6 2/20 0.54
TXNRD2 Q9NNW7 2/20 0.54
CYP1A1 P04798 1/20 0.54
CYP1A2 P05177 1/20 0.54
COPS5 Q92905 1/20 0.54
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
MAPT P10636 4/20 0.44
THRB P10828 4/20 0.44
BLM P54132 4/20 0.44
USP2 O75604 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 3/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
HPGD P15428 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407772 0.75 S100A4 (0.44) CDC25BTXNRD1AURKAAURKBTXNRD3
SCHEMBL7179176 0.75 CDC25B (0.44) CDC25BTXNRD1AURKAAURKBTXNRD3
SCHEMBL29145973 0.74 MAPT (0.40) CDC25BTXNRD1AURKAAURKBTXNRD3
SCHEMBL15478974 0.72 S100A4 (0.41) CDC25BTXNRD1AURKAAURKBTXNRD3
Naphthazalin SCHEMBL149279 0.71 TXNRD1 (1.00) CDC25BTXNRD1AURKAAURKBTXNRD3
Naphthazalin SCHEMBL27700955 0.71 TXNRD1 (1.00) CDC25BTXNRD1AURKAAURKBTXNRD3
Naphthazalin SCHEMBL29353283 0.71 TXNRD1 (1.00) CDC25BTXNRD1AURKAAURKBTXNRD3
SCHEMBL6409655 0.71 TOP1 (0.49) CDC25BTXNRD1TXNRD3TXNRD2MEN1
SCHEMBL7177840 0.70 S100A4 (0.41) CDC25BMEN1KMT2AALDH1A1HPGD
Naphthazalin SCHEMBL21403377 0.69 TXNRD1 (0.94) CDC25BTXNRD1AURKAAURKBTXNRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0804163-B1 IMPROVED METHOD FOR STABILIZATION OF BIOLOGICAL SUBSTANCES DURING DRYING AND SUBSEQUENT STORAGE AND COMPOSITIONS THEREOF ELAN DRUG DELIVERY LTD (GB) 2003-11-12 EP claimed
US-6313102-B1 STABILIZED DRY COMPOSITION COMPRISING THERAPEUTIC AGENT SUSCEPTIBLE TO MAILLARD REACTION, FURTHER COMPRISING REDUCING CARBOHYDRATE AS STABILIZER FOR THERAPEUTIC AGENT AND INHIBITOR OF MAILLARD REACTION QUARDRANT HOLDINGS CAMBRIDGE, LTD. (GB) 2001-11-06 US claimed
US-6290991-B1 POLYOL AND A BIOACTIVE AGENT WHEREIN SAID POLYOL IS AMORPHOUS OR NON-CRYSTALLINE AND STABILIZES SAID BIOACTIVE AGENT, AND WHEREIN SAID THERAPEUTIC COMPOSITION IS A POWDER SUITABLE FOR ADMINISTRATION BY INHALATION QUANDRANT HOLDINGS CAMBRIDGE LIMITED (GB) 2001-09-18 US claimed
US-5955448-A Method for stabilization of biological substances during drying and subsequent storage and compositions thereof QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1999-09-21 US claimed
EP-0804163-A1 IMPROVED METHOD FOR STABILIZATION OF BIOLOGICAL SUBSTANCES DURING DRYING AND SUBSEQUENT STORAGE AND COMPOSITIONS THEREOF QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1997-11-05 EP claimed
CN-1160345-A Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof QUADRANT HOLDINGS CAMBRIDGE (GB) 1997-09-24 CN claimed
EP-0433679-B1 Pharmaceutical compositions for inhibition of maillard's reaction SENJU PHARMA CO (JP) 1997-05-02 EP claimed
WO-1996005809-A1 IMPROVED METHOD FOR STABILIZATION OF BIOLOGICAL SUBSTANCES DURING DRYING AND SUBSEQUENT STORAGE AND COMPOSITIONS THEREOF QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1996-02-29 WO claimed
EP-0433679-A2 Pharmaceutical compositions for inhibition of maillard's reaction Senju Pharmaceutical Co., Ltd. (JP) 1991-06-26 EP claimed
EP-2395073-B1 Drying process GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2017-09-06 EP disclosed
EP-1556477-B1 DRYING PROCESS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2017-08-09 EP disclosed
US-8449865-B2 Drying process GLAXOSMITHKLINE BIOLOGICALS SA. (BE) 2013-05-28 US disclosed
US-8409587-B2 Immunogenic composition GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2013-04-02 US disclosed
US-8173411-B2 Drying process for preserving an active agent as a highly viscous liquid GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2012-05-08 US disclosed
EP-0755249-A1 USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF AMYLOIDOSIS-BASED DISEASE QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1997-01-29 EP disclosed
WO-1996040077-A2 METHODS FOR STABLY INCORPORATING SUBSTANCES WITHIN DRY, FOAMED GLASS MATRICES AND COMPOSITIONS OBTAINED THEREBY QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1996-12-19 WO disclosed
WO-1996005809-A1 IMPROVED METHOD FOR STABILIZATION OF BIOLOGICAL SUBSTANCES DURING DRYING AND SUBSEQUENT STORAGE AND COMPOSITIONS THEREOF QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1996-02-29 WO disclosed
WO-1996003978-A1 SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1996-02-15 WO disclosed
WO-1995028151-A1 USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF AMYLOIDOSIS-BASED DISEASE QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1995-10-26 WO disclosed
EP-0433679-A2 Pharmaceutical compositions for inhibition of maillard's reaction Senju Pharmaceutical Co., Ltd. (JP) 1991-06-26 EP disclosed